KSHB: Kansas City Doctors Are at Center of Breakthrough Research for Heart Failure Patients

A global 52-week trial found overweight or obese heart failure patients who took a weekly injection of semaglutide, commonly known as Ozempic or Wegovy, saw an improvement in their symptoms — shortness of breath, fatigue, swelling, and inability to exercise.

KSHB talked to Dr. Mikhail Kosiborod, a cardiologist at Saint Luke’s Mid America Heart Institute and the study’s lead investigator, and Nancy Collins, a patient who was enrolled in the study. 

Watch the full story below. 

Related Content

Aug. 25, 2023

CNN: Weight-Loss Drug Wegovy Produces ‘Largest Benefit Ever Seen’ for Patients with Most Common Form of Heart Failure, Trial Finds

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.
Aug. 26, 2023

Good Morning America: New Study Highlights Benefits to Weight Loss Drugs

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.
Aug. 25, 2023

MEDIA COVERAGE: Obesity Medication Proves Effective in Treating Patients with Heart Failure

STEP-HFpEF trial findings were presented during the opening late breaking clinical trial session at the European Society of Cardiology Congress in Amsterdam, Netherlands.